Reported Severe GI Reactions to Darolutamide
Darolutamide (Nubeqa), used for non-metastatic castration-resistant prostate cancer, lists gastrointestinal disorders as common adverse reactions in its prescribing information. Severe cases, including grade 3-4 events, have been reported in clinical trials and post-marketing data.
Key Trial Data on GI Events
In the ARAMIS trial (phase 3, n=1,706), darolutamide plus androgen deprivation therapy showed:
- Grade 3-4 GI disorders in 2.1% of patients vs. 0.9% on placebo.[1]
- Specific severe events: diarrhea (0.4%), nausea (0.2%), and vomiting (0.2%).[1]
No GI perforations or obstructions reached grade 3-4 in this trial, but milder GI issues like nausea (15%), diarrhea (9.6%), and decreased appetite (7.9%) were more frequent.[1]
The ARASENS trial (phase 3, n=1,305) reported grade 3-4 GI disorders in 3.6% vs. 2.3% placebo, with diarrhea as the main contributor (1.3%).[2]
Post-Marketing and Real-World Reports
FDA adverse event reporting (FAERS) includes cases of severe GI reactions like colitis, gastrointestinal hemorrhage, and intestinal obstruction linked to darolutamide.[3] European Medicines Agency (EMA) pharmacovigilance data notes rare severe cases of enterocolitis and GI perforation.[4]
A 2023 real-world study in 1,200+ patients found grade ≥3 GI toxicity in 1.8%, mostly diarrhea and nausea.[5]
Comparison to Other Androgen Receptor Inhibitors
| Drug | Severe GI Rate (Grade 3-4, Trials) | Common Severe Events |
|------|------------------------------------|----------------------|
| Darolutamide | 2-3.6% | Diarrhea, nausea |
| Enzalutamide | 1-2% | Diarrhea, vomiting[6] |
| Apalutamide | 4-5% | Diarrhea, nausea[7] |
Darolutamide has a lower CNS penetration, potentially reducing overall toxicity, but GI profiles are similar across the class.
Risk Factors and Management
Higher risk in patients with prior GI disease or combo therapies (e.g., docetaxel in ARASENS). Monitor for dehydration from diarrhea; discontinue if grade 4 or life-threatening.[1] No specific GI warnings added post-approval, unlike some competitors.
[1]: Nubeqa Prescribing Information (FDA)
[2]: NEJM ARASENS Publication
[3]: FDA FAERS Database Query
[4]: EMA Nubeqa EPAR
[5]: J Clin Oncol 2023 Real-World Study
[6]: Xtandi Label
[7]: Erleada Label